» Articles » PMID: 28646112

CRISPR-Cas12a-Assisted Recombineering in Bacteria

Overview
Date 2017 Jun 25
PMID 28646112
Citations 85
Authors
Affiliations
Soon will be listed here.
Abstract

Clustered regularly interspaced short palindromic repeat (CRISPR)-Cas12a (Cpf1) has emerged as an effective genome editing tool in many organisms. Here, we developed and optimized a CRISPR-Cas12a-assisted recombineering system to facilitate genetic manipulation in bacteria. Using this system, point mutations, deletions, insertions, and gene replacements can be easily generated on the chromosome or native plasmids in , , and Because CRISPR-Cas12a-assisted recombineering does not require introduction of an antibiotic resistance gene into the chromosome to select for recombinants, it is an efficient approach for generating markerless and scarless mutations in bacteria. The CRISPR-Cas9 system has been widely used to facilitate genome editing in many bacteria. CRISPR-Cas12a (Cpf1), a new type of CRISPR-Cas system, allows efficient genome editing in bacteria when combined with recombineering. Cas12a and Cas9 recognize different target sites, which allows for more precise selection of the cleavage target and introduction of the desired mutation. In addition, CRISPR-Cas12a-assisted recombineering can be used for genetic manipulation of plasmids and plasmid curing. Finally, Cas12a-assisted recombineering in the generation of point mutations, deletions, insertions, and replacements in bacteria has been systematically analyzed. Taken together, our findings will guide efficient Cas12a-mediated genome editing in bacteria.

Citing Articles

Molecular turn in pathogenesis: implications of the frameshift for bacterial survival in human macrophage.

Chen H, Cao S, Zhou Y, Wang T, Jiao Y, Tan Y Emerg Microbes Infect. 2025; 14(1):2467778.

PMID: 39945756 PMC: 11878169. DOI: 10.1080/22221751.2025.2467778.


Current Knowledge on CRISPR Strategies Against Antimicrobial-Resistant Bacteria.

de la Fuente Tagarro C, Martin-Gonzalez D, De Lucas A, Bordel S, Santos-Beneit F Antibiotics (Basel). 2025; 13(12.

PMID: 39766530 PMC: 11672446. DOI: 10.3390/antibiotics13121141.


ClpS Directs Degradation of N-Degron Substrates With Primary Destabilizing Residues in Mycolicibacterium smegmatis.

Presloid C, Jiang J, Kandel P, Anderson H, Beardslee P, Swayne T Mol Microbiol. 2024; 123(1):16-30.

PMID: 39626090 PMC: 11717620. DOI: 10.1111/mmi.15334.


Revolutionizing Tuberculosis Management With Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas Technology: A Comprehensive Literature Review.

Shetty A, Kwas H, Rajhi H, Rangareddy H, Fryer J Cureus. 2024; 16(10):e71697.

PMID: 39552996 PMC: 11568648. DOI: 10.7759/cureus.71697.


Delivery of functional Cas:DNA nucleoprotein complexes into recipient bacteria through a type IV secretion system.

Guzman-Herrador D, Fernandez-Gomez A, Depardieu F, Bikard D, Llosa M Proc Natl Acad Sci U S A. 2024; 121(43):e2408509121.

PMID: 39413137 PMC: 11513951. DOI: 10.1073/pnas.2408509121.


References
1.
Kim D, Kim J, Hur J, Been K, Yoon S, Kim J . Genome-wide analysis reveals specificities of Cpf1 endonucleases in human cells. Nat Biotechnol. 2016; 34(8):863-8. DOI: 10.1038/nbt.3609. View

2.
Pelicic V, Reyrat J, Gicquel B . Generation of unmarked directed mutations in mycobacteria, using sucrose counter-selectable suicide vectors. Mol Microbiol. 1996; 20(5):919-25. DOI: 10.1111/j.1365-2958.1996.tb02533.x. View

3.
Fonfara I, Richter H, Bratovic M, Le Rhun A, Charpentier E . The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA. Nature. 2016; 532(7600):517-21. DOI: 10.1038/nature17945. View

4.
Grigoriev A . Analyzing genomes with cumulative skew diagrams. Nucleic Acids Res. 1998; 26(10):2286-90. PMC: 147580. DOI: 10.1093/nar/26.10.2286. View

5.
Grote A, Hiller K, Scheer M, Munch R, Nortemann B, Hempel D . JCat: a novel tool to adapt codon usage of a target gene to its potential expression host. Nucleic Acids Res. 2005; 33(Web Server issue):W526-31. PMC: 1160137. DOI: 10.1093/nar/gki376. View